Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies

References

• Nathan DM, BuseJB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. EndocrPract. 2009;15:540–59.
   Google Scholar
• Kulasa K, Edelman S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid. 2010;5:23–37.
   PubMedGoogle Scholar
• Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, . A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16–27.
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485–94.
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, . Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
   PubMed Web of Science ®Google Scholar
• TRADJENTA® (linagliptin). Full prescribing information.Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 2011.
   Google Scholar
• JANUVIA® (sitagliptin). Full prescribing information. Merck & Co, Whitehouse Station, NJ, USA; 2010.
   Google Scholar
• GALVUS (vildagliptin). Prescribing information. Novartis Europharm Ltd, West Sussex, UK; 2011.
   Google Scholar
• ONGLYZA® (saxagliptin). Full prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA; 2011.
   Google Scholar
• Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract. 2010;90:131–40.
   PubMed Web of Science ®Google Scholar
• KOMBIGLYZE XR® (saxagliptin and extended-release metformin hydrochloride). Full prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA; 2010.
   Google Scholar
• Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249–62.
   PubMed Web of Science ®Google Scholar
• Kirby M, Yu DMT, O'Connor SP, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond). 2010;118:31–41.
   Web of Science ®Google Scholar
• Patel CG, Kornhauser D, Vachharajani N, Komoroski B, Brenner E, Handschuh Del Corral M, . Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of 3 oral antidiabetic drugs (metformin, glyburide, or pioglitazone) in healthy subjects. Diabetes Obes Metab. 2011;13:604–14.
   PubMed Web of Science ®Google Scholar
• Patel CG, Girgis S, Kornhauser DM. Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended release, and ketoconazole. Clin Pharmacol Adv App. 2011; 3:13–25.
   PubMedGoogle Scholar
• Rosenstock J. Clinical overview of saxagliptin for type 2 diabetes management. Exp Rev Endocrinol Metab. 2010; 5:809–23.
   PubMedGoogle Scholar
• Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25:2401–11.
   PubMed Web of Science ®Google Scholar
• Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810–9.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, YuyanDuan R, Ravichandran S, . The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649–55.
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611–22.
   PubMed Web of Science ®Google Scholar
• Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63:1395–406.
   PubMed Web of Science ®Google Scholar
• Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26:2355–63.
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, . Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–63.
   PubMed Web of Science ®Google Scholar
• Chen R, Donovan M, Rusnak JM. Saxagliptin used as monotherapy or in combination with other antihyperglycemic agents does not significantly increase risk of hypoglycemia [abstract]. Diabetes. 2009;58(suppl 1): 2082–PO.http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1& CID=74195. Accessed August 4, 2011.
   Google Scholar
• Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64:1619–31.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540–9.
   PubMed Web of Science ®Google Scholar
• Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I, . Saxagliptin improvesglycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011; 13:523–32.
   PubMed Web of Science ®Google Scholar
• AVANDIA® (rosiglitazome maleate). Full prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA; 2011.
   Google Scholar
• Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009;7:324–42.
   PubMed Web of Science ®Google Scholar
• GLUCOPHAGE®, GLUCOPHAGE® XR (metformin hydrochloride, extended-release metformin hydrochloride). Full prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA; 2009.
   Google Scholar
• BYETTA® (exenatide). Full prescribing information. Amylin Pharnaceuticals, San Diego, CA, USA; 2010.
   Google Scholar
• PRECOSE® (acarbose). Full prescribing information. Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA; 2008.
   Google Scholar
• Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27:863–9.
   PubMed Web of Science ®Google Scholar
• Maheux P, Donovan M, Allen E, Berglind N, Bouzamondo H. Efficacy of saxagliptin in relation to baseline HbA1c in a pooled analysis of three add-on pivotal randomised phase 3 clinical trials [abstract]. European Association for the Study of Diabetes 46th Annual Meeting; 20–24 September 2010; Stockholm, Sweden.
   Google Scholar
• Allen E, Donovan M, Berglind N, Maheux P. Efficacy of saxagliptin according to patient baseline characteristics: a pooled analysis of 3 add-on pivotal randomised phase 3 clinical trials [abstract]. European Association for the Study of Diabetes 46th Annual Meeting; 20–24 September 2010; Stockholm, Sweden.
   Google Scholar
• Does saxagliptin reduce the risk of cardiovascular events when used alone or added to other diabetes medications (SAVOR-TIMI 53);2011. Available at: clinicaltrials.gov/ct2/show/NCT01107886?term=NCT01107886&rank = 1 (accessed 13 May 2011).
   Google Scholar
• DeFronzo R, Hissa MN, Garber AJ, Gross JL, DuanRY, Ravichandran S, . Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes. 2009;58:547–P.
   Google Scholar
• Hollander PL, Jia L, Frederich R, Allen E, Chen R; CV181013 Investigators. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011;8:125–35.
   PubMed Web of Science ®Google Scholar
• Chacra AR, Tan GH, Ravichandran S, List J, Chen R; CV181040 Investigators. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011;8:150–9.
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13:567–76.
   PubMed Web of Science ®Google Scholar